KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Income from Continuing Operations data on record, last reported at 1191100000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 30.46% year-over-year to 1191100000.0; the TTM value through Dec 2025 reached 3953200000.0, up 838.09%, while the annual FY2025 figure was 3953200000.0, 838.09% up from the prior year.
  • Income from Continuing Operations reached 1191100000.0 in Q4 2025 per VRTX's latest filing, up from 1082900000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1191100000.0 in Q4 2025 and bottomed at 3593600000.0 in Q2 2024.
  • Average Income from Continuing Operations over 5 years is 635069100.0, with a median of 882491000.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 1109.7% in 2022, then tumbled 492.44% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 770100000.0 in 2021, then rose by 6.34% to 818900000.0 in 2022, then increased by 18.31% to 968800000.0 in 2023, then decreased by 5.76% to 913000000.0 in 2024, then skyrocketed by 30.46% to 1191100000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 1191100000.0 in Q4 2025, 1082900000.0 in Q3 2025, and 1032900000.0 in Q2 2025.